Shots:

• The P-III CANOPY-1 trial evaluates canakinumab (ACZ885) + pembrolizumab + platinum-based doublet CT vs PBO + pembrolizumab + CT in patients with LA or metastatic NSCLC
• The trial did not meet its 1EPs of OS and PFS and showed improvements in PFS & OS in pre-specified subgroups of patients based on the baseline inflammatory biomarker- hs-CRP along with other biomarker-defined subgroups
• The results further support the continued study of P-III CANOPY-A for canakinumab in earlier stages of lung cancer as potential adjuvant & P-II CANOPY-N study in the neoadjuvant therapies. Patients in the CANOPY-A study more closely reflect the earlier CANTOS study population compared to the CANOPY-1 trial

 ­ Ref: Novartis | Image: Novartis